Navigation Links
Genedata Screener Global User Group Meetings Will Examine Advancements in Plate-based Screening
Date:9/4/2013

Basel, Switzerland (PRWEB) September 04, 2013

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that four Genedata Screener User Group Meetings will be held in Asia, Europe, and North America during September 2013. Annual global meetings bring together scientists, lab heads, bioinformaticians, and research IT managers from leading pharmaceutical and biotechnology companies, academic institutions, and contract research organizations. With more than half of the top 25 pharmaceutical companies using Genedata Screener, industry experts from AstraZeneca, Eli Lilly, and Vertex Pharmaceuticals will be among the featured speakers who represent a growing community of researchers who run screening experiments for Compound Combination, Ion Channel, high-throughput screening, high-content screening, and label-free data analysis.

“Genedata Screener User Group Meetings underscore one of the core values at Genedata – namely that of collaboration,” said Dr. Othmar Pfannes, CEO of Genedata. “They provide real-life opportunities for Screener users to meet their peers, learn, share experiences, and discover more applications for Genedata Screener. This level of global collaboration fuels continuous technology innovations from Genedata.”

The 2013 Genedata Screener User Group Meetings will also feature Best Practice sessions on topics such as “Feature Selection in HCS Assays” and “Compound Profiling with Hit Profiler.” Meetings will be held in: Tokyo, Japan (Sept. 3); Basel, Switzerland (Sept. 10); Boston, MA (Sept.17); and San Francisco, CA (Sept. 19). Inquiries may be sent to: ugm(at)genedata(dot)com.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11083970.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Screener Extends Support for High-Throughput Thermofluor Assays
2. Genedata at ESACT Announces Expansion Into Biopharma Process Development
3. New Genedata Expressionist for Mass Spectrometry Showcases at 2013 ASMS
4. AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization
5. Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
6. Genedata Screener 11 with Compound Combination Screening and Collaboration in the Cloud Announced at Bio-IT World 2013
7. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
8. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
9. Ono Pharmaceutical Selects Genedata Expressionist for Mass Spectrometry
10. Genedata Biologics 3.0 Boosts Efficiency Through Standardization
11. Genedata Screener Adopted for all Plate-based Screening by Major Pharmas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on ... of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ... is expected to deliver therapeutic levels of olanzapine for a period of 3 months., ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing ... financial results for the third quarter and first nine ... Third Quarter of Fiscal 2017 Highlights ... 2017 increased by 18.6% to RMB200.9 million ($28.9 million). ...
Breaking Biology Technology:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
Breaking Biology News(10 mins):